

## A LINEAR TIME-COURSE MODEL

Pandey S<sup>1</sup>, Singh B<sup>2</sup>, Bajaj P<sup>1</sup>, Sharma A<sup>2</sup><sup>1</sup>Heorlytics Pvt. Ltd., SAS Nagar, India, <sup>2</sup>Pharmacoevidence Ltd., London, UK

## OBJECTIVE

To generate evidence from more than one study with multiple treatments at different follow-up times

## BACKGROUND

- Network Meta-Analysis (NMA) is used to generate evidence from more than one study with multiple treatments but lacks efficiency and accuracy when studies report findings at different follow-up times
- NMA can increase the precision of estimates compared with standard pairwise meta-analysis, but it relies on the consistency assumption that there is no difference between direct and indirect evidence
- For establishing a time-course relationship a parametric functional form was required. Model-based network meta-analysis (MBNMA) which is a general framework for NMA that incorporates parametric models of time-course relationships has been established
- The benefit of this approach compared with NMA is that it allows the inclusion of studies with different follow-up times, and therefore provides the possibility of including clinical trials from earlier in clinical development

## RESULTS

- Results of the linear time-course model were examined using the forest plot & prediction plot
- The method generates a network of comparisons across multiple treatments over different time points and the posterior median with 95% credible intervals for the change in efficacy for each treatment versus treatment of interest has been calculated
- The posterior median and 95% credible intervals for treatment B vs A: -0.87 (-2.32, 0.38) whereas for treatment C vs A: -0.74 (-2.08, 0.49), treatment D vs A: -0.64 (-1.95, 0.62), treatment E vs A: -0.59 (-1.90, 0.77)

Figure 1: Network Plot showing the connection of different studies with treatments





Figure 2 : Forest Plot showing posterior median with CIs for All vs. Treatment A



## Reference

Pedder H, Boucher M, Dias S, Bennetts M, Welton NJ. Performance of model-based network meta-analysis (MBNMA) of time-course relationships: A simulation study. Res Synth Methods. 2020 Sep;11(5):678-697. DOI: 10.1002/jrsm.1432. Epub 2020 Aug 4. PMID: 32662206.

## METHODOLOGY

- MBNMA<sup>1</sup> is a new technique for evidence synthesis that allows the incorporation of a parametric time course in NMA, which enables the inclusion of studies with different follow-up times in a manner that explains heterogeneity/inconsistency
- By pooling relative effects within studies, time-course MBNMA preserves randomization and allows for testing of consistency between direct and indirect evidence in the network, whilst making use of all the available evidence at different time points
- “MBNMAtime” package in R was adopted to perform a meta-analysis of studies with multiple follow-up measurements in order to account for linear time-course relationships with multiple treatment comparisons. The analysis was performed in R v4.2.1
- The package allows a range of different time-course models to be fitted in a Bayesian framework such as Log-linear time-course MBNMA, Piecewise linear time-course MBNMA with a knot at different time points, Emax time-course MBNMA, Emax time-course MBNMA with two parameters, B-spline time-course MBNMA and many more

Figure 3: Time Plot showing the mean response of treatments at different time points





Figure 4: Prediction Plot showing the response of treatments at different time points (Reference = Treatment A)



## CONCLUSION

- MBNMA works efficiently and effectively on data sets including multiple treatments at multiple follow-up times and is statistically robust for synthesizing direct and indirect evidence to estimate relative effects- supporting its use in evidence synthesis. The results obtained from the linear time-course MBNMA model suggest that all the relative effects obtained are statistically insignificant
- By demonstrating that time-course can be included in NMA in a statistically robust manner, we hope that this will allow the inclusion of trials from drug development into reimbursement agency decision-making. Doing so can help to bridge the gap in evidence synthesis technique that currently exist between Pharmacometrics and Health Technology Appraisal

For any queries contact: [Shubhram.pandey@heorlytics.com](mailto:Shubhram.pandey@heorlytics.com)

Presented at ISPOR Europe • Vienna, Austria, November 6-9, 2022